NCT03630159View on ClinicalTrials.gov

Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 9, 2018

Primary Completion Date

July 20, 2021

Study Completion Date

July 20, 2021

Conditions
Diffuse Large B-cell Lymphoma
Interventions
BIOLOGICAL

Tisagenlecleucel

Gene modified autologous T cells

DRUG

Pembrolizumab

anti PD-1

Trial Locations (5)

1090

Novartis Investigative Site, Vienna

30322

Emory University School of Medicine SC CTL019, Atlanta

60637

University of Chicago Medical Center Hematology and Oncology, Chicago

66160

University of Kansas Hospital and Medical Center U of Kansas Cancer Center, Kansas City

H1T 2M4

Novartis Investigative Site, Montreal

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY